Radiation therapy improves cancer cure rates by killing cancer cells but it also contributes to long-term side effects in cancer survivors by unintentionally damaging normal organs such as the intestine. This research will what side effects patients with cancer experience, if high dose vitamin C helps reduce these side effects, and if high dose vitamin C increases the survival of patients with pancreatic cancer. We will meet with patients during the study to better understand their experience during their cancer treatment. In the long term, our research could provide a new way help cancer survivors avoid many permanent side effects of cancer treatments.

Start Date31 Dec 2025

Sponsor / Collaborator

The Holden Comprehensive Cancer Center

NCT06823999

/ Not yet recruitingPhase 4IIT

Effect of Vitamin C in the Prevention and Treatment for Bruises in Patients with Ischemic Stroke: a Double-blind Randomized Control Trial

Background Over the past few decades, significant advances have been made in the diagnosis and treatment of strokes. Most studies focus on functional recovery in stroke patients. In addition to motor function, there are many symptoms may affect function and quality of life in stroke patients. Bruises are caused by damage to the skin that causes blood to drain out of the capillaries and accumulate in the connective tissue of the skin or subcutaneous tissue. The study on non-motor syndrome in ischemic stroke patients found that 25.8% of ischemic stroke patients had bruises and 17.7% of bruises were unexplained bruises. In addition to the physiological and emotional effects on stroke patients, bruises may increase infection risk and affect stroke patient outcomes. Vitamin C is a natural antioxidant discovered in 1747 to treat and prevent scurvy. Vitamin C can reduce gum bleeding and prevent colon bleeding after a polypectomy. Vitamin C has been reported to reduce brain edema around brain injury and decrease mortality in patients with traumatic brain injury. Dehydroascorbic acid decreases infarct volume in mice with middle cerebral artery occlusion. Investigators hypothesized that administration of vitamin C to patients with acute ischemic stroke patients would decrease the risk of bleeding and enhance its resolution. Investigators also hypothesized that vitamin C injection could minimize infarct volume and improve outcomes in ischemic stroke patients. The aims of the study include: 1. To investigate whether vitamin C injections can reduce bruising risk and enhance bruising resolution. 2. To explore whether vitamin C injections in the acute phase of stroke can improve the prognosis of ischemic stroke patients.
Methods This is a prospective, double-blind, randomized controlled study. All patients admitted to the hospital under the diagnosis of ischemic stroke and stroke was confirmed by Magnetic Resonance imaging (MRI) or brain computed imaging (CT) and aged between 20 and 85 years were invited to participate in the study. Investigators excluded patients who had these diseases: cancer receiving chemotherapy, end stage renal disease receiving dialysis, autoimmune disease, hematological disease, Glucose-6-phosphatase disease, gouty arthritis, and a lack of informed consent.
During the study period, all patients who met the inclusion and exclusion criteria were invited to participate in the study. After informed consent, participants were randomly assigned to the experimental group or the control group. All participants underwent NIHSS evaluation and a detailed dermatological examination on the day of hospitalization. After enrollment, the experimental group received 4 mg Vitamin C injection per day for 4 days, while the control group received the same volume of normal saline injection per day for 4 days. Researchers evaluate participant skin condition (including bruises number and size, color) every day during hospitalization, and up to 1 month after stroke. Investigators evaluate NIHSS at discharge and follow-up functional outcome (mRS) up to 3 months after stroke onset.
Analysis Rate shows bruise percentage. Chi square or Fisher exact test was applied to compare the difference in bruises between two groups. Logistic regression was used to compare bruise risk between groups. Wilcoxon rank sign test was used to analyze stroke severity and outcome between two groups.

Start Date01 Aug 2025

Sponsor / Collaborator

Chiayi Christian Hospital

ACTRN12625000178448

/ Not yet recruitingPhase 1IIT

An open label pilot feasibility study of 30% sodium asCOrbate aS OSMOtherapy in patientS with traumatic brain injury and raised intracranial pressure

Start Date03 Mar 2025

Sponsor / Collaborator

Monash University

100 Clinical Results associated with Ascorbic Acid

100 Translational Medicine associated with Ascorbic Acid

100 Patents (Medical) associated with Ascorbic Acid

193,881

Literatures (Medical) associated with Ascorbic Acid

31 Dec 2025·The Journal of Maternal-Fetal & Neonatal Medicine

Assessing the relationship between serum vitamin A, C, E, D, and B12 levels and preeclampsia

Article

Author: Hu, Zhenhua ; Yang, Wenjiao ; Gu, Weirong

OBJECTIVEMicronutrients play an important role in maintaining physiological functions while preventing complications associated with pregnancy. The main aim of this study was to evaluate the possible associations between vitamins A, C, D, E, B12, and preeclampsia using a retrospective analytical approach.METHODSThis retrospective study enrolled pregnant women who attended routine antenatal checkups between January 2021 and January 2023 at the Obstetrics and Gynecology Hospital of Fudan University. One thousand pregnant women aged 18-50 years whose serum vitamin assessments were conducted during 12-20 weeks of gestation were enrolled. Inclusion criteria: women with preeclampsia, singleton pregnancies, and no previous history of hypertension or preeclampsia. Exclusion criteria: metabolic disorders, multiple pregnancies, and other specified exclusions. Approval of the hospital's ethics committee; all participants gave written informed consent. Demographic data analyzed include age, BMI, and gestational age, showing no significant differences in age span between groups (p > .05).RESULTSIn the preeclampsia group, the serum level of vitamin A stands at 1.08 ± 0.29 μmol/L, which is lower than the control group of 1.13 ± 0.31 μmol/L (p < .05). Mean serum levels of vitamin C in preeclampsia are 51.81 ± 13.15 μmol/L, which was lower than in the control group, where it was 59.67 ± 16.40 μmol/L (p < .05). The mean serum vitamin B12 level in preeclampsia is 158.28 ± 46.77 pmol/L, lower than the 165.61 ± 40.99 pmol in the control group (p < .05). The two groups had no significant difference in serum vitamin E and vitamin D levels (p > .05).CONCLUSIONSerum vitamins A, C, and B12 at 12 to 20 weeks of pregnancy might be important predisposing factors for preeclampsia. They can be used as indicators of preeclampsia severity and offer clinical detection even before the patient presents with symptoms.

01 Dec 2025·Tropical Plant Biology

Bioactive Metabolites and ISSR Marker Assisted Selection Demonstrate the Diversity in Clitoria ternatea L. (Leguminosae) Morphotypes

Author: Dan, Mathew ; Beevy, S. Suhara ; R, Arya M.

Abstract: Clitoria ternatea L.(Family: Fabaceae) comprises two varieties, namely, C. ternatea var. ternatea (Papilionaceous form) and C. ternatea var. pleniflora (Non-papilionaceous form).The proposed study compared seven morphotypes of C. ternatea exhibiting different flower colors and symmetry with their profiled bioactive metabolites and ISSR markers.A phytochem. study was performed on fresh floral methanolic extracts to estimate total flavonoid, total anthocyanin (Cyanidin and Delphinidin equivalent), and total phenolic content.The genotypes showed varied amounts of these constituents, with the highest quantities found in the Single Blue morphotype for phenolic and Cyanidin equivalent, while the Double Blue morphotype exhibited the highest flavonoid and Delphinidin content.The antioxidant potential of the Double Blue morphotype was comparable to ascorbic acid in the DPPH radical scavenging assay.Addnl., ISSR markers effectively distinguished morphotypes based on floral color and symmetry.From an initial 30 primers, 20 generated clear, reproducible polymorphic bands.UBC 868 amplified the highest number of bands, while UBC 890 showed complete monomorphism across all varieties with 21 monomorphic bands.The average resolving power was 2.267, and UBC 810 demonstrated significant discriminating power among morphotypes.UBC 855 revealed distinctive patterns in double petal forms, whereas UBC 872 served as a floral color-specific marker, differentiating blue morphotypes from others.This study helps to compare the intraspecific variants differing in color and floral architecture, establishing a correlation between phytochem. profiles and petal coloration, thereby enhancing the understanding of this species′ diversity.

01 Jun 2025·Gold Bulletin

Simple process for the recovery of gold metals and palladium(II) compound from aqua regia etching solutions of printed circuit boards by chemical reduction and precipitation

Author: Nguyen, Thi Nhan Hau ; Lee, Man Seung

Printed circuit boards (PCBs) contain precious metals like gold and palladium.After pre-treatment, PCBs are dissolved with aqua regia to recover precious metals.Reduction and precipitations experiments were done to recover gold metal and palladium(II) compound from PCB etching solutions which contained Au(III), Pd(II), Al(III), Cu(II), Fe(III), Ni(II), Sn(II), and Zn(II).In the first step, Au(III) ions were chem. reduced to gold metal using ascorbic acid without changing the acidity of the solutionThe optimal conditions for the reduction were 1.5 for the molar ratio of ascorbic acid to Au(III) at room temperature for 30 min.Then, PdI₂ was recovered from the filtrate by using NaI as a precipitant.The optimal conditions for this precipitation were a NaI/Pd(II) molar ratio of 7 at room temperature for 60 min.The purity of the gold metal and PdI₂ was verified by measuring the composition of the solution after dissolving with aqua regia.A simple process was proposed to recover gold metal and PdI₂ powders with 99.9% purity from the etching solutions of PCBs at room temperature

News (Medical) associated with Ascorbic Acid

28 Jan 2025

·www.prnewswire.com

Debut Unveils AI-powered Ingredient Discovery Platform to Fuel Biotech Innovation for All Beauty Brands Globally through Partner KDC/one

New discovery engine, BeautyORB™ by Debut, will create two novel, peak-performing biotech ingredients each year, giving beauty brands access to game-changing clinical claims and product innovation. Debut's new partnership with contract manufacturer KDC/one enables brands of all sizes to harness the power of biotech. SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Debut, the biotech beauty leader, announced today the launch of BeautyORB™, an AI-powered innovation engine that provides a new way to discover novel ingredients for best-in-class claims for beauty brands, from a typical time horizon of several years to two Debut ingredients launched each year. The genomics-based AI platform, which is on par with pharmaceutical-grade technology, has already fueled the creation of groundbreaking ingredients addressing inflammaging, epidermal barrier repair and longevity, with brightening, anti-aging and scalp care ingredients already in the pipeline. Continue Reading Image Credit: Billy Economou, BE Studios "With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction. This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims," said Joshua Britton, Ph.D, Founder and CEO of Debut. "We don't have to rely on an array of existing ingredients to test against specific claims, and we don't have to go into the field to find rare ingredients in plants. All this can be done at the click of a button, cutting out years from the innovation cycle and accessing ingredients that no one has seen before. We can turn on and off molecular pathways differently and use AI to discover what molecules can affect those pathways. The result is a rich, proven and growing pipeline of novel ingredients with the strongest clinical results for our customers, allowing brands to win on product performance rather than marketing". BeautyORB™ discovers new ingredients by screening 50 billion molecules for their ability to turn on cellular pathways within skin, a process that has never previously been possible in beauty. Debut's AI platform has already identified three novel, patented ingredients that achieve the highest beauty standards including scientifically-proven, clinically-tested and 100% bio-based ingredients that beat existing benchmarks. These ingredients include: DermCeutical InflammagePRO™: Best-in-class for inflammaging. Decreases inflammatory markers, supports the skin barrier and enhances elasticity. 15X better than niacinamide. DermCeutical Barrier RepairPRO™: Best-in-class for epidermal barrier repair. Defends the skin against damage from environmental aggressors. 30% better than vitamin C for skin damage repair. DermCeutical LongevityPRO™: Best-in-class for cellular longevity. Decreases markers of cellular senescence and helps maintain healthy skin cells. 2X better than vitamin C for skin health. "With BeautyORB™, we can develop ingredients that have the targeted responses we seek, using the same technology to find ingredients that fight disease. Our tool is another key step in the convergence of pharma and beauty. We are thrilled to partner with the industry leading contract manufacturer KDC/one to create finished products of the highest quality, in tandem with Debut's custom formulation business, BiotechXBeautyLabs™, to achieve our mission of reinventing product performance with the safest sustainability credentials. Our KDC/one partnership sets the stage for a global biomanufacturing revolution in beauty," said Britton. BeautyORB™ is the latest tool to emerge from Debut's ongoing commitment to lead the beauty industry's shift to biotech, creating a community of future-forward brands and product innovators that solve existing and emerging consumer needs. Using generative AI, BeautyORB™ delivers: More than 50 billion molecule possibilities 30,000 genes tested per molecule using omics technology 25,000 genes tested per second 21,000 molecules screened in silico per second for deep learning 200+ new biological pathways tested per molecule Over 60 million data points, with 100 million over the next 12 months About Debut The leader in biotech beauty Debut is pioneering the beauty industry's shift from traditionally sourced ingredients derived from petroleum and cultivation to high-performing and inherently sustainable biotech ingredients. As a fully vertically-integrated global company, Debut creates superior, scientifically-engineered, bio-based and clinically-proven products and brands at scale to benefit people and planet. Our mission is to create a new beauty standard based on potency, purity, and performance. About KDC/one Industry leading Contract Manufacturer KDC/one's Beauty & Personal Care manufacturing platform includes state-of-the-art facilities across North America, Europe, and Asia, allowing us to seamlessly deliver solutions for the complex production requirements of our global customers. With a global network of manufacturing, R&D, innovation hubs, and showrooms, KDC/one has end-to-end capabilities across formulation, design, packaging, and manufacturing to service a wide range of customer types, from start-up brands to multinational consumer companies. SOURCE Debut Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

26 Dec 2024

·www.prnewswire.com

Researchers from Korea University Explore How Ascorbic acid and FGF4 Revolutionize Regenerative Medicine

Korean scientists discover a groundbreaking method to transform ordinary fibroblasts into mature cardiomyocytes SEOUL, South Korea, Dec. 26, 2024 /PRNewswire/ -- Researchers at Korea University have achieved a significant breakthrough in regenerative medicine. They have demonstrated how fibroblast growth factor 4 and Ascorbic acid, known as vitamin C, can induce the trans-differentiation of fibroblasts into functional cardiomyocytes. This discovery activates key cellular pathways and offers hope for developing treatments for cardiovascular diseases, the leading cause of death worldwide. Continue Reading This diagram illustrates how the combination of fibroblast growth factor 4 and ascorbic acid activates the JAK2-STAT3 signaling pathway, promoting the maturation of induced cardiomyocytes (iCMs). This approach effectively reprograms fibroblasts into cardiomyocytes with improved structure and function, offering exciting possibilities for regenerative medicine. Cardiovascular disease continues to lead as the primary cause of death across the globe, taking millions of lives every year. Damage caused by these diseases is particularly difficult to repair, since the heart has minimal ability to regenerate itself. But what if we could reprogram the body's own cells to restore damaged tissue? This groundbreaking question has been tackled by scientists at Korea University, led by Dr. Myeong-Hwa Song. The team has unveiled an innovative technique to convert fibroblasts—common connective tissue cells—into mature and functional induced cardiomyocytes (iCMs). Their method relies on combining fibroblast growth factor 4 (FGF4) with vitamin C, a pairing that accelerates cell maturation and enhances function. "Our findings bring us closer to transforming regenerative medicine into practical therapies," says Dr. Song, who is based at Korea University's Department of Cardiology and in Seoul, South Korea. "This research takes an important step toward using a patient's own cells to repair their heart." Direct cardiac reprogramming, a process that bypasses the intermediate stem cell stage, allows fibroblasts to be converted into iCMs. While this approach holds significant promise, scientists have struggled to produce mature and fully functional cardiomyocytes. The Korea University team addressed this hurdle by activating a critical cellular mechanism: the JAK2–STAT3 signaling pathway. Through their research, the scientists employed advanced techniques like RNA sequencing, fluorescence imaging, and electrophysiological testing. Their results revealed key improvements: better cell structure with well-defined sarcomeres and T-tubules, enhanced electrical activity with improved ion channel function, and a higher efficiency in generating mature, fully reprogrammed cardiomyocytes. Dr. Song explained that the JAK2-STAT3 pathway was crucial to these outcomes, enabling the induction of cells that closely mimic the structure and function of natural cardiomyocytes. This discovery, published in Experimental & Molecular Medicine on October 10, 2024, holds tremendous promise for regenerative medicine. By promoting mature cardiomyocytes from a patient's own tissue, it may one day be possible to repair damage from heart attacks or other cardiovascular conditions. Such an approach could reduce reliance on heart transplants and potentially revolutionize treatments for millions of patients. However, further studies are necessary to ensure this method is both safe and effective for clinical use. "We're thrilled with these results, but this is just the beginning," says Prof. Song. "More research will be required before we can bring this approach to patients. That said, the possibilities are incredibly exciting." If translated into therapy, this technique could provide a personalized solution for regenerating heart tissue, establishing a significant advance in combating cardiovascular disease. Reference Title of original paper: FGF4 and ascorbic acid enhance the maturation of induced cardiomyocytes by activating JAK2–STAT3 signaling Journal: Experimental & Molecular Medicine DOI: About Korea University College of Medicine Website: Contact: Yoo-Jung Lee +82 2 2286-1131 [email protected] SOURCE Korea University College of Medicine WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Cell Therapy

11 Dec 2024

·www.prnewswire.com

Elume Offers Fuss-Free Skincare Solutions for All Skin Tones

The Indian Skincare Brand Is Empowering Women Around the World With Simple, Pleasant, Effective Skincare Solutions FORT LAUDERDALE, Fla., Dec. 11, 2024 /PRNewswire/ -- Elume is a forward-thinking skincare company that is empowering women through simple, streamlined, and effective skincare solutions for all skin tones. The breakout Indian brand's inclusive emphasis comes from its focus on its Asian-first philosophy and its desire to meet the unique needs of the Asian consumer. Elume has created its popular and diverse skincare range through a combination of simple choices and thorough education. The company focuses on reducing overwhelm through easily accessible information and positive experiences. "Our goal is to create pleasant, fuss-free experiences for everyone, no matter their skin tone or skincare needs," said Elume co-founder Pavneet. "Élume is more than a skincare brand; it's a celebration of diversity and natural beauty. Our products, enriched with potent ingredients like Vitamin C and Niacinamide, are crafted to meet the unique needs of people with melanated skin, ensuring they receive the care and nourishment their skin deserves." As a way to make the skincare journey easier, Elume has put a heavy emphasis on transparency throughout its business activity. Formulas are easy to find and presented in concise yet comprehensive formats. This makes it easier for customers to make the best choice based on their unique skin needs. In addition, the company has an entire page devoted to ingredient descriptions to further promote education and wise purchase decisions. There is also a clear dual focus on prevention and treatment. Some products help maintain healthy skin, while others address specific concerns and conditions. One of the best examples of Elume's comprehensive and effective approach to global skincare is its Vitamin C+ range. The popular product line includes a cleanser, toner, serum, and moisturizer, all with clear descriptions and applications. The collection is celebrated for brightening and revitalizing the skin and the ability to consistently deliver exceptional results based on clearly communicated expectations. The brand has similar products formulated for skin radiance, acne, hyperpigmentation, and aging skin. Elume is more than a skincare brand. On the surface, its products offer a proactive approach to skincare, ensuring long-term skin wellness and vitality. But it goes further. The company is also committed to exceptional service as it cares for consumers and gives them the confidence to care for their bodies without the need to cover up or alter them. About Elume Elume is a brand from Skin Habits Pvt. Ltd. and was launched in 2021 in the heart of North India, Chandigarh. The company operates with family values and an emphasis on a better tomorrow. This primarily focuses on leaving behind old, harmful ideologies that have resonated for generations. The Elume team has over 20 years of expertise in skincare and embraces an Asian-first philosophy founded on meticulous research in the areas of melanated skin, tropical weather, and a fast-paced lifestyle. Its products are dermatologically tested, PETA-approved cruelty-free, and manufactured at a WHO GMP-certified factory. Learn more at elume.in. Arvin Mondal Director, International Business Development M: +91 991 590 0348 E: [email protected] SOURCE Elume WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Ascorbic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D00018	Ascorbic Acid	G01AD03 S01XA15	DB00126

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Avitaminosis	Japan	NISSIN Pharmaceutical Co., Ltd.	15 May 1990
Ascorbic Acid Deficiency	Japan	neo CritiCare Phama Co., Ltd.	09 Sep 1985
Iron Overload	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Methemoglobinemia	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Scurvy	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Multiple Myeloma	Phase 3	United States	The Cleveland Clinic Foundation	03 Jun 2005
Relapse multiple myeloma	Phase 3	United States	The Cleveland Clinic Foundation	03 Jun 2005
Nutritional and Metabolic Diseases	Phase 2	United States	Beth Israel Deaconess Medical Center, Inc.	09 Feb 2018
Shock, Septic	Phase 2	United States	Beth Israel Deaconess Medical Center, Inc.	09 Feb 2018
Adenocarcinoma of large intestine	Phase 2	United States	Weill Medical College of Cornell University	29 Mar 2017
Pancreatic Cancer	Phase 2	United States	Weill Medical College of Cornell University	29 Mar 2017
metastatic non-small cell lung cancer	Phase 2	United States	McGuff Pharmaceuticals, Inc.	01 Apr 2015
Bacterial Vaginosis	Phase 2	China	Shenyang Huatai Medication Research Co., Ltd.	09 Jan 2015
Feeding and Eating Disorders	Phase 2	Brazil	EMS SA (Brazil)	01 Oct 2011
Gingivitis	Phase 2	Japan	Lion Corp.	01 Sep 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05501548 (CTgov)	Phase 2	Castration-Resistant Prostatic Cancer	4	Olaparib+Vitamin C	clzecqihya(nwuuaqdtpo) = fkvtwytyda wtpbvolycb (oouzvvsjcu, egiknetyld - ntrkyzwbmp) View more	-	29 Jan 2025
ESMO_ASIA2024	Not Applicable	Mucositis	60	Vitamin C and Zinc injections	uzvfriafqj(ojaltuxhkq) = pbskbvwmqu tfqvqlfcaf (jpjyicuzmz ) View more	Positive	07 Dec 2024
				vitamin C (Standard care)	uzvfriafqj(ojaltuxhkq) = eeuwayxvnz tfqvqlfcaf (jpjyicuzmz ) View more
ASH2024	Not Applicable	Chronic Myelomonocytic Leukemia	-	High dose ascorbate	cdnqpxurgp(nmwexqaric) = increased total 5hmC levels kweemknmnv (popwfuwqjz ) View more	-	07 Dec 2024
NCT02905578 (Pubmed \| Redox Biol)	Phase 2	Metastatic Pancreatic Cancer	-	Gemcitabine and nab-paclitaxel only	(hhvqmimjps) = cbcmrzsoia ftpqfcknrp (rgqfyufoow ) View more	-	01 Nov 2024
				Gemcitabine and nab-paclitaxel + Pharmacological ascorbate (P-AscH<sup>-</sup>)	(hhvqmimjps) = mzjjvlnaah ftpqfcknrp (rgqfyufoow ) View more
NCT04291508 (ASTER, CTgov)	Phase 2	Respiratory Failure \| Critical Illness \| Sepsis \| Respiratory Distress Syndrome, Acute	488	Intravenous Acetaminophen (room temperature) (IV Acetaminophen-Active)	ickrohaakv(txnbezdaot) = yjbsshznwx nuwzhtqtrr (ximllykwwp, xcklpgipwv - tdrprxytox) View more	-	27 Sep 2024
				Intravenous Vitamin C (refrigerated) (IV Vitamin C-Active)	ickrohaakv(txnbezdaot) = fxgdfubune nuwzhtqtrr (ximllykwwp, hrnketdxjl - evvfbksgmh) View more
NCT01905150 (CTgov)	Phase 2	Pancreatic Cancer	34	VitaminC+G-FLIP-DM (G-FLIP Alone for 4 Weeks, Then G-FLIP+VitaminC. When DP Occurred, Then G-FLIP-DM+VitaminC)	(wslthuyguv) = ggbacahbwt jsnwesfejb (gobtpeddut, fkdxblvyev - ghggxkxhzn) View more	-	14 Aug 2024
				VitaminC+G-FLIP-DM+G-FLIP (G-FLIP+VitaminC. When DP Occurred, Then G-FLIP-DM+Vitamin C.)	(wslthuyguv) = pnganjferw jsnwesfejb (gobtpeddut, nytbvnvhhk - pjuanukwfd) View more
EULAR2024	Not Applicable	Tendinopathy	72	Dietary supplement (chondroitin sulfate, type I collagen, vitamin C, manganese) + corticosteroid injection	zmukltvcwi(yqwjwxpwiu) = 100% in the diacerein group and 0% in the study group hsrolbufzu (qxzkzunrbw ) View more	Positive	05 Jun 2024
				Diacerein + corticosteroid injection
NCT04344184 (CTgov)	Phase 2	Kidney Diseases \| Acute Lung Injury \| COVID-19	47	L-ascorbic acid (Infusion)	anqyctljwp(wzvoifwmbc) = ebhkibvksy wqvtqkioyc (jtchfpcqhz, mulhgzpdio - xugazoepfw) View more	-	04 Apr 2024
				Placebo (Placebo)	anqyctljwp(wzvoifwmbc) = onwtqglvnu wqvtqkioyc (jtchfpcqhz, pvqgccpyog - hetdkecyaw) View more
NCT03433781 (CTgov)	Phase 1/2	Myelodysplastic Syndromes	4	vitamin C (Vitamin C 50 g)	vvwkggkxlo(cyftwlpyhl) = ehsxtrxauc kujczooknw (vlslqhrbnn, ubyrbnxxdg - xdksslsfhf) View more	-	27 Mar 2024
				vitamin C (Vitamin C 75 g)	vvwkggkxlo(cyftwlpyhl) = kipfkgboka kujczooknw (vlslqhrbnn, zjnobchcwt - qsxpqyadsc) View more
NCT04046094 (CTgov)	Phase 1/2	Bladder Cancer	12	Ascorbic Acid	zbracgqaoi(lldotxxced) = pehdcapkxf sjmygddtry (ckqzeobadw, qvzllnahvp - jmtaxlynsn) View more	-	04 Mar 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis